Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced it has repurchased an additional 100,000 shares of common stock in the open market at an average price of about $0.2928 per share. This brings total repurchases under its previously announced up to $5 million share buyback program to 4,588,000 shares for approximately $970,000.
According to Cosmos Health, shares may be repurchased in the open market, through privately negotiated transactions, or other permitted means, in line with SEC Rules 10b5-1 and 10b-18. The program runs through December 31, 2026, may be renewed at the company’s discretion, and the company intends to continue open market repurchases subject to market conditions.
Positive
- 4,588,000 shares repurchased for approximately $970,000 under program
- Buyback authorization size up to $5 million through December 31, 2026
- Company intends to continue open market repurchases, subject to market conditions
Negative
- Share repurchases to date represent a cash outlay of about $970,000
Market reaction after share repurchase program update: COSM -9.31% in the Jul 15 session
In the Jul 15 session, COSM declined 9.31%, reflecting a notable negative market reaction. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Buybacks Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Share repurchase update | Positive | -4.3% | Announced total buybacks of 4,488,000 shares for about $941,000 under program. |
| Jul 13 | Share repurchase update | Positive | +5.4% | Reported buybacks reaching 4,355,000 shares with roughly $901,000 spent. |
| Jul 09 | Share repurchase update | Positive | -1.0% | Expanded buybacks to 4,140,000 shares totaling approximately $831,000. |
| Jul 08 | Share repurchase update | Positive | +2.8% | Disclosed surpassing 4,060,000 shares repurchased for about $811,000. |
| Jul 07 | Share repurchase update | Positive | -4.9% | Reported 3,870,000 shares repurchased for roughly $758,000 under $5M plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent buyback headlines have produced mixed share reactions, with a slight tilt toward negative moves on average.
Key Terms
open market repurchases financial
sec rules 10b5-1 regulatory
sec rules 10b-18 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 100,000 shares of its common stock in the open market at an average price of approximately
The Company has now repurchased a total of 4,588,000 shares for approximately
The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company’s sole discretion.
Greg Siokas, CEO of Cosmos Health, stated: "Surpassing 4.5 million shares repurchased reflects the conviction behind our share repurchase program.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
